These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 35780283)
1. Fusidic acid in a tertiary hospital: an observational study focusing on prescriptions, tolerance and susceptibility of Staphylococcus and Cutibacterium spp. strains from bone samples. Romaru J; Limelette A; Lebrun D; Bonnet M; Garnier VV; N'Guyen Y Eur J Clin Microbiol Infect Dis; 2022 Aug; 41(8):1107-1113. PubMed ID: 35780283 [TBL] [Abstract][Full Text] [Related]
2. Dissemination of fusidic acid resistance among Staphylococcus aureus clinical isolates. Yu F; Liu Y; Lu C; Lv J; Qi X; Ding Y; Li D; Huang X; Hu L; Wang L BMC Microbiol; 2015 Oct; 15():210. PubMed ID: 26463589 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of antibiotic resistance to orally administrable antibiotics in staphylococcal bone and joint infections in one of the largest university hospitals in Germany: is there a role for fusidic acid? Klein S; Nurjadi D; Eigenbrod T; Bode KA Int J Antimicrob Agents; 2016 Feb; 47(2):155-7. PubMed ID: 26774158 [TBL] [Abstract][Full Text] [Related]
4. Susceptibility of Staphylococcus aureus to fusidic acid: Canadian data. Rennie RP J Cutan Med Surg; 2006; 10(6):277-80. PubMed ID: 17241597 [TBL] [Abstract][Full Text] [Related]
5. Fusidic Acid and Its Major Active Metabolite Penetration into Cerebrospinal Fluid for Assessing Treatment of Intracranial Infections. Rao Z; He ZF; Zheng MH; Dang ZL; Yang G; Zhang YH; Lu N; Wei YH Chemotherapy; 2023; 68(1):48-54. PubMed ID: 35810737 [TBL] [Abstract][Full Text] [Related]
6. Fusidic acid in bone and joint infections. Atkins B; Gottlieb T Int J Antimicrob Agents; 1999 Aug; 12 Suppl 2():S79-93. PubMed ID: 10528790 [TBL] [Abstract][Full Text] [Related]
8. In vitro susceptibility of Staphylococcus aureus and coagulase-negative Staphylococcus strains to fusidic acid. Tünger O; Arisoy A; Kurutepe S; Akçali S; Ozbakkaloğlu B Int J Antimicrob Agents; 2001 Nov; 18(5):445-7. PubMed ID: 11711260 [No Abstract] [Full Text] [Related]
9. Mutations in rpoB and fusA cause resistance to rifampicin and fusidic acid in methicillin-resistant Staphylococcus aureus strains from a tertiary hospital in Malaysia. Lim KT; Teh CS; Yusof MY; Thong KL Trans R Soc Trop Med Hyg; 2014 Feb; 108(2):112-8. PubMed ID: 24336696 [TBL] [Abstract][Full Text] [Related]
10. Fusidic acid resistance rates and prevalence of resistance mechanisms among Staphylococcus spp. isolated in North America and Australia, 2007-2008. Castanheira M; Watters AA; Bell JM; Turnidge JD; Jones RN Antimicrob Agents Chemother; 2010 Sep; 54(9):3614-7. PubMed ID: 20566766 [TBL] [Abstract][Full Text] [Related]
11. Disk diffusion interpretive criteria for fusidic acid susceptibility testing of staphylococci by the National Committee for Clinical Laboratory Standards method. Coutant C; Olden D; Bell J; Turnidge JD Diagn Microbiol Infect Dis; 1996 May; 25(1):9-13. PubMed ID: 8831039 [TBL] [Abstract][Full Text] [Related]
12. Staphylococcus aureus resistant to fusidic acid among Swedish children: a follow-up study. Osterlund A; Kahlmeter G; Haeggman S; Olsson-Liljequist B; Scand J Infect Dis; 2006; 38(5):334-4. PubMed ID: 16724423 [TBL] [Abstract][Full Text] [Related]
13. In vitro antimicrobial findings for fusidic acid tested against contemporary (2008-2009) gram-positive organisms collected in the United States. Jones RN; Mendes RE; Sader HS; Castanheira M Clin Infect Dis; 2011 Jun; 52 Suppl 7():S477-86. PubMed ID: 21546624 [TBL] [Abstract][Full Text] [Related]
14. Fusidic acid resistance in community isolates of methicillin-susceptible Staphylococcus aureus and fusidic acid prescribing. Mason BW; Howard AJ; Magee JT J Antimicrob Chemother; 2003 Apr; 51(4):1033-6. PubMed ID: 12654748 [TBL] [Abstract][Full Text] [Related]
15. The independent evolution of resistance to ciprofloxacin, rifampicin, and fusidic acid in methicillin-resistant Staphylococcus aureus in Australian teaching hospitals (1990-1995). Australian Group for Antimicrobial Resistance (AGAR). Gottlieb T; Mitchell D J Antimicrob Chemother; 1998 Jul; 42(1):67-73. PubMed ID: 9700530 [TBL] [Abstract][Full Text] [Related]
16. Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus. Wang JL; Tang HJ; Hsieh PH; Chiu FY; Chen YH; Chang MC; Huang CT; Liu CP; Lau YJ; Hwang KP; Ko WC; Wang CT; Liu CY; Liu CL; Hsueh PR Int J Antimicrob Agents; 2012 Aug; 40(2):103-7. PubMed ID: 22612900 [TBL] [Abstract][Full Text] [Related]
18. Prevalence of fusB in Staphylococcus aureus clinical isolates. Huang J; Ye M; Ding H; Guo Q; Ding B; Wang M J Med Microbiol; 2013 Aug; 62(Pt 8):1199-1203. PubMed ID: 23639984 [TBL] [Abstract][Full Text] [Related]
19. Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus. O'Neill AJ; Cove JH; Chopra I J Antimicrob Chemother; 2001 May; 47(5):647-50. PubMed ID: 11328777 [TBL] [Abstract][Full Text] [Related]
20. Occurrence and molecular characterization of fusidic acid resistance mechanisms among Staphylococcus spp. from European countries (2008). Castanheira M; Watters AA; Mendes RE; Farrell DJ; Jones RN J Antimicrob Chemother; 2010 Jul; 65(7):1353-8. PubMed ID: 20430787 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]